Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.68 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.51 |
| ▸ | PGR | P06401 | 3/20 | 0.50 |
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6654901 | 0.87 | CYP11B2 (0.80) | CYP11B2NR3C1CYP11B1PGRSMO | |
| SCHEMBL15839046 | 0.81 | CYP11B2 (1.00) | CYP11B2NR3C1CYP11B1PGRSMO | |
| SCHEMBL3017074 | 0.81 | CYP11B2 (0.69) | CYP11B2NR3C1CYP11B1SMOCYP1A2 | |
| SCHEMBL15825125 | 0.81 | CYP11B2 (0.69) | CYP11B2NR3C1CYP11B1CYP19A1PGR | |
| SCHEMBL413216 | 0.81 | CYP11B2 (0.69) | CYP11B2NR3C1CYP11B1PGRSMO | |
| SCHEMBL6653634 | 0.78 | CYP11B2 (0.65) | CYP11B2CYP11B1CYP17A1SMOCYP1A2 | |
| SCHEMBL30708157 | 0.78 | CYP11B2 (0.65) | CYP11B2CYP11B1CYP17A1SMOCYP1A2 | |
| SCHEMBL6846125 | 0.78 | CYP11B2 (0.59) | CYP11B2CYP11B1CYP19A1CYP17A1ALDH1A1 | |
| SCHEMBL30864253 | 0.76 | CYP11B2 (0.63) | CYP11B2NR3C1CYP11B1SMOALDH1A1 | |
| SCHEMBL15839035 | 0.76 | CYP11B2 (0.71) | CYP11B2NR3C1CYP11B1PGRSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | CYP11B2 53/4885NR3C1 2336/4885CYP11B1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.